AI Article Synopsis
- The study aimed to explore the clinical features and treatment methods for prostatic mucinous adenocarcinoma (PMAC) by analyzing 10 cases treated at Nanjing Medical University between 2014 and 2018.
- All surgeries were successful, with pathological findings indicating a mix of cancer stages and some patients showing signs of recurrence; follow-up showed 4 patients had biochemical recurrence within 2 years and required additional treatments to lower their PSA levels.
- The research concluded that PMAC generally has a favorable prognosis, suggesting radical surgery is suitable for lower-risk cases, and comprehensive treatment options are beneficial for those who experience recurrence post-surgery.*
Article Abstract
Objective: To investigate the clinical characteristics and treatment strategies of prostatic mucinous adenocarcinoma (PMAC).
Methods: We retrospectively analyzed the clinical data on 10 cases of PMAC treated in the First Affiliated Hospital of Nanjing Medical University from January 2014 to June 2018. The patients were aged 51－79 (65 ± 14) years, with a medium PSA level of 89 (14.63－128.05) μg/L and Gleason scores of 3 + 3 in 1 case, 3 + 4 in 2, 4 + 3 in 1 and 8 in 6 cases preoperatively, 1 treated by robot-assisted radical prostatectomy and the other 9 by laparoscopic radical prostatectomy. We conducted pelvic cavity lymph node dissection for all the patients and analyzed their prognosis and survival.
Results: Operations were successfully completed in all the cases. Pathological examination revealed 2 cases of mucinous adenocarcinoma with signet ring cell carcinoma in the 10 PMAC patients, 2 at stage ≤T2b, 5 at stage ≥T2c, 3 positive at pelvic lymph node dissection and 5 positive at the incision margin. The patients were followed up for 6－48 (median 26) months. Four of the patients were found with biochemical recurrence within 2 years after operation and treated by androgen-deprivation therapy, radiotherapy and chemotherapy, which reduced the PSA level to <1.0 μg/ml in all the 4 cases.
Conclusions: PMAC has a good prognosis. Radical surgery is recommended for moderate and low-risk PMAC and the patients with postoperative biochemical recurrence can benefit from comprehensive treatment of total androgen blockade.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!